CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Atezolizumabdrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03526900
NCT03526900Phase 2Completed
CompareCT.gov

Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naïve and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis

Spanish Lung Cancer Group·interventional·Posted May 16, 2018·Updated Oct 9, 2024

In Brief

A Phase 2 clinical trial evaluating Atezolizumab for Non-small Cell Lung Cancer Stage IV. Completed, enrolled 40 participants across 15 sites.

Detailed Summary

This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM. A pre-screening period using brain MRI for patients diagnosed with advanced non-squamous NSCLC EGFR/ALK wild type and ECOG PS 0-1 will be crucial to identify patients with asyntomatic BM. Forty patients will be recruited.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer Stage IV
CountriesSpain
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 16, 2018
Enrollment StartJul 7, 2018
Primary CompletionMar 31, 2022
Study CompletionSep 15, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.1 years ago

Interventions

Atezolizumabdrug

* Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2 * Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2.